Pharmaceutical company Yukang Health-B (02617): The global multicenter Phase III clinical trial of single-agent treatment with Tegafur in patients with advanced bile duct cancer has completed enrollment.

The iAsk Financial APP reports that Pharmaron Health-B (02617) has announced that the global multicenter Phase III clinical trial for its core product, Tinengotinib (TT00420), for the treatment of advanced bile duct cancer patients, has recently completed the planned subject enrollment.